Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Oligo-mannurarate (GV-971) in Mild to Moderate Alzheimer's Disease
NCT02293915Phase 3Completed
- Sponsor
- Green Valley
- Start
- Apr 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing GV-971 with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive subscale 12-item at 36 weeks. Started Apr 2014; status: completed.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02293915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293915.